{"id":"pramipexole-or-ropinirole","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Dizziness"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Dyskinesia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This leads to increased dopamine activity in the brain, which can help alleviate symptoms of Parkinson's disease and restless legs syndrome. By activating dopamine receptors, these drugs can also help regulate movement and reduce symptoms of these conditions.","oneSentence":"Pramipexole and ropinirole are dopamine agonists that activate dopamine receptors in the brain, mimicking the action of dopamine.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:29:53.239Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Parkinson's disease"},{"name":"Restless legs syndrome"}]},"trialDetails":[{"nctId":"NCT02138357","phase":"PHASE4","title":"Butrans for Treatment of Restless Legs Syndrome","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2014-04","conditions":"Restless Legs Syndrome","enrollment":""},{"nctId":"NCT01976871","phase":"PHASE4","title":"Switching From Oral Dopamine Agonists to Rotigotine","status":"COMPLETED","sponsor":"John Winkelman, MD, PhD","startDate":"2014-08","conditions":"Restless Legs Syndrome, Ekbom Syndrome, Willis-Ekbom Disease","enrollment":21},{"nctId":"NCT01052831","phase":"PHASE4","title":"Naltrexone for Impulse Control Disorders in Parkinson's Disease","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2009-11","conditions":"Impulse Control Disorder, Parkinson Disease","enrollment":50},{"nctId":"NCT00242008","phase":"PHASE3","title":"A Trial To Assess Switching From Ropinirole, Pramipexole Or Cabergoline To The Rotigotine Transdermal System In Idiopathic Parkinson's Disease","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2004-12","conditions":"Parkinson's Disease","enrollment":""},{"nctId":"NCT01723904","phase":"PHASE3","title":"A Phase 3b, Open-Label, Safety and Efficacy Study of Rotigotine as Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"UCB BIOSCIENCES GmbH","startDate":"2012-10","conditions":"Advanced Parkinson's Disease","enrollment":90},{"nctId":"NCT01711866","phase":"PHASE4","title":"A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms of Switching From Pramipexole or Ropinirole to Rotigotine Transdermal Patch in Subjects With Advanced Idiopathic Parkinson's Disease","status":"COMPLETED","sponsor":"UCB BIOSCIENCES GmbH","startDate":"2012-09","conditions":"Advanced Idiopathic Parkinson's Disease","enrollment":87},{"nctId":"NCT00605683","phase":"PHASE3","title":"MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist","status":"COMPLETED","sponsor":"Newron Pharmaceuticals SPA","startDate":"2007-11","conditions":"Idiopathic Parkinson's Disease","enrollment":679},{"nctId":"NCT00986245","phase":"PHASE4","title":"Study to Compare the Effect of Ropinirole Prolonged Release Once-daily Versus Twice-daily","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2009-09","conditions":"Parkinson Disease","enrollment":82},{"nctId":"NCT00275275","phase":"PHASE3","title":"Pramipexole Conversion to Ropinirole Controlled Release (CR)","status":"COMPLETED","sponsor":"Rajesh Pahwa, MD","startDate":"2006-01","conditions":"Parkinson Disease","enrollment":61},{"nctId":"NCT01007864","phase":"PHASE3","title":"Influence of Piribedil (Clarium®) on Vigilance and Cognitive Function in Patients With Parkinson's Disease Compared to Other Non-Ergot Dopamine Agonists","status":"COMPLETED","sponsor":"Desitin Arzneimittel GmbH","startDate":"2010-01","conditions":"Idiopathic Parkinson's Disease","enrollment":80},{"nctId":"NCT01515774","phase":"PHASE4","title":"Study to Observe the Effect of Mirapex ER® Once-daily (QD) Versus Twice-daily (BID)","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2011-09","conditions":"Parkinson's Disease","enrollment":200},{"nctId":"NCT00344994","phase":"PHASE4","title":"SWITCH:Restless Legs Patients Switched to Ropinirole From Pramipexole","status":"COMPLETED","sponsor":"Augusta University","startDate":"2006-05","conditions":"Restless Legs Syndrome","enrollment":20},{"nctId":"NCT00399477","phase":"PHASE4","title":"A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease","status":"COMPLETED","sponsor":"Teva Neuroscience, Inc.","startDate":"2006-10","conditions":"Parkinson's Disease","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"pramipexole or ropinirole","genericName":"pramipexole or ropinirole","companyName":"Desitin Arzneimittel GmbH","companyId":"desitin-arzneimittel-gmbh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pramipexole and ropinirole are dopamine agonists that activate dopamine receptors in the brain, mimicking the action of dopamine. Used for Parkinson's disease, Restless legs syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}